Link N Peptide Fragments Stimulate Cartilage Matrix Synthesis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for cartilage and intervertebral disc disorders, such as osteoarthritis and degenerative disc disease, lack effective methods for repairing or reversing cartilage and disc degeneration, relying on surgical interventions that can lead to biomechanical changes and adjacent-level disc degeneration, with no therapies capable of reversing cartilage degradation.

Innovation Solution

The use of Link N fragments, specifically peptides like DHLSDNYT and DHHSDNYT, to induce proteoglycan and collagen synthesis in cartilage and disc cells, promoting matrix repair and potentially treating disorders like arthritis and intervertebral disc degeneration by enhancing extracellular matrix production and reducing inflammatory cytokine activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If surgical excision, cage insertion, or vertebral bone fusion is performed to treat IVD degeneration, then pain relief is achieved in the short term, but spine biomechanics are altered leading to adjacent-level disc degeneration

Engineering Contradiction:
Improvepain reliefVSAvoidadjacent-level disc degeneration
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention segments the full-length link protein into smaller functional fragments (such as N-terminal fragments containing the first 16 amino acids) that retain the ability to stimulate proteoglycan synthesis. This segmentation allows the therapeutic effect to be achieved with a smaller, more manageable peptide that can be administered systemically without the complications of larger protein therapy, while still providing the benefit of biological repair to prevent adjacent-level degeneration.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The link protein fragment acts as an intermediary substance that mediates between the administered therapy and the degenerating disc tissue. It stimulates endogenous proteoglycan synthesis by disc cells, serving as a biological mediator that promotes tissue repair and maintains spine biomechanics, thereby preventing adjacent-level disc degeneration while providing pain relief.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If growth factors such as TGF-β and BMP 7 are used to promote ECM production and downregulate proteinase activity, then cartilage and disc repair is enhanced, but cost increases and potential side effects arise

Engineering Contradiction:
Improvecartilage and disc repairVSAvoidcost and side effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention uses a short-lived peptide fragment (16 amino acids) instead of expensive, complex growth factors. This small peptide can be synthesized cost-effectively and administered as a temporary therapy that stimulates endogenous repair mechanisms. The fragment's short half-life reduces the risk of long-term side effects while still providing the necessary stimulus for proteoglycan synthesis and tissue repair.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The invention changes the molecular parameters from large, complex growth factors (TGF-β, BMP 7) to a small peptide fragment with 16 amino acids. This parameter change dramatically reduces cost and potential side effects while maintaining the therapeutic function of stimulating proteoglycan synthesis and promoting cartilage and disc repair through activation of specific signaling pathways.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If proteases are inhibited to prevent ECM degradation, then structural failure and loss of IVD height are reduced, but normal tissue remodeling processes are also impaired

Engineering Contradiction:
Improvestructural integrityVSAvoidtissue remodeling
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The invention converts the harmful effect of proteases (which cause ECM degradation) into a beneficial process by stimulating proteoglycan synthesis. The link protein fragment activates disc cells to produce new proteoglycans that replace degraded ECM components. This approach maintains the natural proteolytic remodeling process while simultaneously enhancing tissue repair through increased proteoglycan production, thereby preserving both structural integrity and normal tissue remodeling.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Link N fragments stimulate proteoglycan and collagen synthesis in both healthy and degenerative conditions, including inflammatory environments, effectively increasing matrix production and potentially alleviating symptoms of cartilage and disc disorders, offering a biological repair approach to existing surgical-centric treatments.

Implementation Method 1

Link N fragments stimulate proteoglycan and collagen synthesis in both healthy and degenerative conditions

Methodology Applied
Scientific EffectProteoglycan synthesis:

Implementation Method 2

Link N fragments stimulate proteoglycan and collagen synthesis in both healthy and degenerative conditions

Methodology Applied
Scientific EffectCollagen synthesis:

Implementation Method 3

enhancing extracellular matrix production and reducing inflammatory cytokine activity

Methodology Applied
Scientific EffectAnti-inflammatory activity:

Data Source

PatentEP3039032B1Methods and compositions for treatment of cartilage and disc tissue pathologies
Publication Date: 2021.05.19 MCGILL UNIV
  • EP3039032B1 patent drawingFigure 1a~1b
  • EP3039032B1 patent drawingFigure 2~3b
  • EP3039032B1 patent drawingFigure 4a~4c

AI summary

An isolated polypeptide comprising a peptide selected from: i) DHX1SDNYT, wherein X1 is L or H (SEQ ID NO:3); ii) a conservative variant of i) iii) a fragment of i) or ii); wherein the conservative variant and/or fragment retains biological activity and the peptide is 15 or less amino acids as well as recombinant cells, and uses thereof.